nodes	percent_of_prediction	percent_of_DWPC	metapath
Rasagiline—BCL2—Inflammasomes—P2RX7—multiple sclerosis	0.0179	0.0607	CbGpPWpGaD
Rasagiline—BCL2—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—P2RX7—multiple sclerosis	0.00858	0.0292	CbGpPWpGaD
Rasagiline—BCL2—IL2 signaling events mediated by STAT5—FOXP3—multiple sclerosis	0.00714	0.0243	CbGpPWpGaD
Rasagiline—BCL2—ATF-2 transcription factor network—IL23A—multiple sclerosis	0.00699	0.0238	CbGpPWpGaD
Rasagiline—MAOB—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.00576	0.0196	CbGpPWpGaD
Rasagiline—MAOB—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.00576	0.0196	CbGpPWpGaD
Rasagiline—BCL2—Validated targets of C-MYC transcriptional repression—ZFP36L1—multiple sclerosis	0.00564	0.0192	CbGpPWpGaD
Rasagiline—BCL2—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—NOD1—multiple sclerosis	0.00475	0.0161	CbGpPWpGaD
Rasagiline—BCL2—HIV-1 Nef: Negative effector of Fas and TNF-alpha—TNFRSF1A—multiple sclerosis	0.00462	0.0157	CbGpPWpGaD
Rasagiline—BCL2—RXR and RAR heterodimerization with other nuclear receptor—VDR—multiple sclerosis	0.00441	0.015	CbGpPWpGaD
Rasagiline—BCL2—Amyotrophic lateral sclerosis (ALS)—TNFRSF1A—multiple sclerosis	0.00413	0.014	CbGpPWpGaD
Rasagiline—BCL2—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—TNFAIP3—multiple sclerosis	0.00404	0.0137	CbGpPWpGaD
Rasagiline—BCL2—ATF-2 transcription factor network—SELE—multiple sclerosis	0.00401	0.0136	CbGpPWpGaD
Rasagiline—BCL2—Validated targets of C-MYC transcriptional repression—SLC11A1—multiple sclerosis	0.00378	0.0128	CbGpPWpGaD
Rasagiline—BCL2—IL2 signaling events mediated by STAT5—IL4—multiple sclerosis	0.00372	0.0126	CbGpPWpGaD
Rasagiline—BCL2—Validated targets of C-MYC transcriptional repression—IRF8—multiple sclerosis	0.00358	0.0122	CbGpPWpGaD
Rasagiline—BCL2—Ceramide signaling pathway—TNFRSF1A—multiple sclerosis	0.00342	0.0116	CbGpPWpGaD
Rasagiline—BCL2—IL2 signaling events mediated by STAT5—IL2RA—multiple sclerosis	0.00341	0.0116	CbGpPWpGaD
Rasagiline—BCL2—HIV-1 Nef: Negative effector of Fas and TNF-alpha—FAS—multiple sclerosis	0.00317	0.0108	CbGpPWpGaD
Rasagiline—MAOB—Biological oxidations—CYP27B1—multiple sclerosis	0.00306	0.0104	CbGpPWpGaD
Rasagiline—MAOB—Biological oxidations—CYP24A1—multiple sclerosis	0.00306	0.0104	CbGpPWpGaD
Rasagiline—BCL2—Caspase Cascade in Apoptosis—TNFRSF1A—multiple sclerosis	0.00298	0.0101	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—IRF5—multiple sclerosis	0.00298	0.0101	CbGpPWpGaD
Rasagiline—BCL2—IL2 signaling events mediated by PI3K—IL2RA—multiple sclerosis	0.00288	0.00979	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—ZMIZ1—multiple sclerosis	0.0028	0.00953	CbGpPWpGaD
Rasagiline—BCL2—IL-3 Signaling Pathway—CD86—multiple sclerosis	0.00263	0.00895	CbGpPWpGaD
Rasagiline—BCL2—FAS pathway and Stress induction of HSP regulation—FAS—multiple sclerosis	0.00262	0.0089	CbGpPWpGaD
Rasagiline—BCL2—IL-2 Signaling Pathway—IL2RA—multiple sclerosis	0.0026	0.00885	CbGpPWpGaD
Rasagiline—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.00259	0.0088	CbGpPWpGaD
Rasagiline—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.00259	0.0088	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—IRF5—multiple sclerosis	0.00249	0.00847	CbGpPWpGaD
Rasagiline—BCL2—TP53 Network—MYC—multiple sclerosis	0.00225	0.00765	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—TNFRSF1A—multiple sclerosis	0.00219	0.00744	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—CCL3—multiple sclerosis	0.00218	0.0074	CbGpPWpGaD
Rasagiline—BCL2—Interleukin-11 Signaling Pathway—ICAM1—multiple sclerosis	0.00217	0.00739	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—IL2RA—multiple sclerosis	0.00213	0.00724	CbGpPWpGaD
Rasagiline—BCL2—Validated targets of C-MYC transcriptional repression—CCL5—multiple sclerosis	0.00212	0.0072	CbGpPWpGaD
Rasagiline—BCL2—Overview of nanoparticle effects—TNF—multiple sclerosis	0.0021	0.00713	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	0.00207	0.00704	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—TNFRSF1A—multiple sclerosis	0.00205	0.00698	CbGpPWpGaD
Rasagiline—BCL2—Caspase Cascade in Apoptosis—FAS—multiple sclerosis	0.00205	0.00697	CbGpPWpGaD
Rasagiline—BCL2—IL2 signaling events mediated by STAT5—IL2—multiple sclerosis	0.002	0.00679	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—IRF5—multiple sclerosis	0.00198	0.00673	CbGpPWpGaD
Rasagiline—BCL2—Estrogen signaling pathway—MAPK1—multiple sclerosis	0.00189	0.00642	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—IFNB1—multiple sclerosis	0.00182	0.00618	CbGpPWpGaD
Rasagiline—BCL2—Interleukin-11 Signaling Pathway—TYK2—multiple sclerosis	0.00177	0.00601	CbGpPWpGaD
Rasagiline—BCL2—RXR and RAR heterodimerization with other nuclear receptor—TGFB1—multiple sclerosis	0.00175	0.00594	CbGpPWpGaD
Rasagiline—BCL2—Overview of nanoparticle effects—IL6—multiple sclerosis	0.00169	0.00575	CbGpPWpGaD
Rasagiline—BCL2—IL2 signaling events mediated by PI3K—IL2—multiple sclerosis	0.00169	0.00574	CbGpPWpGaD
Rasagiline—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.00164	0.00558	CbGpPWpGaD
Rasagiline—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.00164	0.00558	CbGpPWpGaD
Rasagiline—BCL2—RXR and RAR heterodimerization with other nuclear receptor—TNF—multiple sclerosis	0.00163	0.00554	CbGpPWpGaD
Rasagiline—CYP1A2—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.00162	0.00551	CbGpPWpGaD
Rasagiline—CYP1A2—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.00162	0.00551	CbGpPWpGaD
Rasagiline—BCL2—IL-5 Signaling Pathway—IL2—multiple sclerosis	0.00159	0.00539	CbGpPWpGaD
Rasagiline—BCL2—IL2 signaling events mediated by STAT5—MYC—multiple sclerosis	0.00156	0.00531	CbGpPWpGaD
Rasagiline—BCL2—IL-2 Signaling Pathway—IL2—multiple sclerosis	0.00153	0.00519	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—FAS—multiple sclerosis	0.0015	0.00511	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—FAS—multiple sclerosis	0.00141	0.00479	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12A—multiple sclerosis	0.00141	0.00479	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—IFNG—multiple sclerosis	0.0014	0.00477	CbGpPWpGaD
Rasagiline—BCL2—HIV-1 Nef: Negative effector of Fas and TNF-alpha—TNF—multiple sclerosis	0.00135	0.00458	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—TNFRSF1A—multiple sclerosis	0.00134	0.00456	CbGpPWpGaD
Rasagiline—BCL2—IL-5 Signaling Pathway—STAT3—multiple sclerosis	0.00133	0.00454	CbGpPWpGaD
Rasagiline—CYP1A2—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.00133	0.00453	CbGpPWpGaD
Rasagiline—CYP1A2—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.00133	0.00453	CbGpPWpGaD
Rasagiline—BCL2—IL2 signaling events mediated by PI3K—MYC—multiple sclerosis	0.00132	0.00449	CbGpPWpGaD
Rasagiline—BCL2—ATF-2 transcription factor network—IFNG—multiple sclerosis	0.00131	0.00445	CbGpPWpGaD
Rasagiline—MAOB—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.00129	0.0044	CbGpPWpGaD
Rasagiline—BCL2—IL-2 Signaling Pathway—STAT3—multiple sclerosis	0.00128	0.00436	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—TLR4—multiple sclerosis	0.00126	0.00427	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—IL2—multiple sclerosis	0.00125	0.00424	CbGpPWpGaD
Rasagiline—BCL2—IL-5 Signaling Pathway—MYC—multiple sclerosis	0.00124	0.00422	CbGpPWpGaD
Rasagiline—BCL2—Interleukin-11 Signaling Pathway—STAT3—multiple sclerosis	0.00124	0.0042	CbGpPWpGaD
Rasagiline—BCL2—IL-5 Signaling Pathway—MAPK1—multiple sclerosis	0.00121	0.00413	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—P2RX7—multiple sclerosis	0.00121	0.00412	CbGpPWpGaD
Rasagiline—BCL2—Amyotrophic lateral sclerosis (ALS)—TNF—multiple sclerosis	0.0012	0.00409	CbGpPWpGaD
Rasagiline—BCL2—IL-2 Signaling Pathway—MYC—multiple sclerosis	0.00119	0.00406	CbGpPWpGaD
Rasagiline—BCL2—IL-2 Signaling Pathway—MAPK1—multiple sclerosis	0.00117	0.00397	CbGpPWpGaD
Rasagiline—BCL2—Integrated Cancer Pathway—MYC—multiple sclerosis	0.00115	0.00391	CbGpPWpGaD
Rasagiline—BCL2—Interleukin-11 Signaling Pathway—TGFB1—multiple sclerosis	0.00115	0.0039	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—VDR—multiple sclerosis	0.00115	0.00389	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—ITGA4—multiple sclerosis	0.00114	0.00387	CbGpPWpGaD
Rasagiline—BCL2—IL-3 Signaling Pathway—STAT3—multiple sclerosis	0.00113	0.00386	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	0.00113	0.00386	CbGpPWpGaD
Rasagiline—BCL2—Interleukin-11 Signaling Pathway—MAPK1—multiple sclerosis	0.00112	0.00382	CbGpPWpGaD
Rasagiline—BCL2—FAS pathway and Stress induction of HSP regulation—TNF—multiple sclerosis	0.00111	0.00378	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—POMC—multiple sclerosis	0.0011	0.00375	CbGpPWpGaD
Rasagiline—BCL2—Signaling events mediated by Stem cell factor receptor (c-Kit)—STAT3—multiple sclerosis	0.0011	0.00374	CbGpPWpGaD
Rasagiline—BCL2—Ceramide signaling pathway—MYC—multiple sclerosis	0.00107	0.00364	CbGpPWpGaD
Rasagiline—BCL2—IL-3 Signaling Pathway—TGFB1—multiple sclerosis	0.00105	0.00358	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—STAT3—multiple sclerosis	0.00105	0.00357	CbGpPWpGaD
Rasagiline—BCL2—Ceramide signaling pathway—MAPK1—multiple sclerosis	0.00105	0.00357	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—SPP1—multiple sclerosis	0.00104	0.00352	CbGpPWpGaD
Rasagiline—BCL2—IL-3 Signaling Pathway—MAPK1—multiple sclerosis	0.00103	0.00351	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—FAS—multiple sclerosis	0.000999	0.0034	CbGpPWpGaD
Rasagiline—BCL2—Ceramide signaling pathway—TNF—multiple sclerosis	0.000999	0.00339	CbGpPWpGaD
Rasagiline—BCL2—Kit receptor signaling pathway—STAT3—multiple sclerosis	0.000978	0.00333	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—MYC—multiple sclerosis	0.000976	0.00332	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—C4A—multiple sclerosis	0.000959	0.00326	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—MAPK1—multiple sclerosis	0.000955	0.00324	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—CD4—multiple sclerosis	0.000952	0.00324	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—FAS—multiple sclerosis	0.000921	0.00313	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	0.000911	0.0031	CbGpPWpGaD
Rasagiline—BCL2—ATF-2 transcription factor network—MAPK1—multiple sclerosis	0.000889	0.00302	CbGpPWpGaD
Rasagiline—BCL2—Kit receptor signaling pathway—MAPK1—multiple sclerosis	0.000889	0.00302	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—multiple sclerosis	0.000885	0.00301	CbGpPWpGaD
Rasagiline—BCL2—Caspase Cascade in Apoptosis—TNF—multiple sclerosis	0.00087	0.00296	CbGpPWpGaD
Rasagiline—BCL2—Validated targets of C-MYC transcriptional repression—MYC—multiple sclerosis	0.000863	0.00293	CbGpPWpGaD
Rasagiline—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000847	0.00288	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—IFNG—multiple sclerosis	0.000825	0.0028	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—IL2—multiple sclerosis	0.000815	0.00277	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—SPP1—multiple sclerosis	0.000811	0.00276	CbGpPWpGaD
Rasagiline—CYP1A2—Estrogen Receptor Pathway—STAT3—multiple sclerosis	0.000782	0.00266	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	0.000779	0.00265	CbGpPWpGaD
Rasagiline—CYP1A2—Melatonin metabolism and effects—APOE—multiple sclerosis	0.00077	0.00262	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—SRM—multiple sclerosis	0.000742	0.00252	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—IL1B—multiple sclerosis	0.000736	0.0025	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—CYP24A1—multiple sclerosis	0.000708	0.00241	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—CYP27B1—multiple sclerosis	0.000708	0.00241	CbGpPWpGaD
Rasagiline—BCL2—Immune System—P2RX7—multiple sclerosis	0.000707	0.0024	CbGpPWpGaD
Rasagiline—CYP1A2—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000698	0.00237	CbGpPWpGaD
Rasagiline—CYP1A2—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000698	0.00237	CbGpPWpGaD
Rasagiline—MAOB—Biological oxidations—POMC—multiple sclerosis	0.000688	0.00234	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—MYC—multiple sclerosis	0.000685	0.00233	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—MYC—multiple sclerosis	0.000685	0.00233	CbGpPWpGaD
Rasagiline—BCL2—ATF-2 transcription factor network—IL6—multiple sclerosis	0.000683	0.00232	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—NOD1—multiple sclerosis	0.000671	0.00228	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CD226—multiple sclerosis	0.000657	0.00223	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—MALT1—multiple sclerosis	0.000648	0.0022	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—TNF—multiple sclerosis	0.000638	0.00217	CbGpPWpGaD
Rasagiline—BCL2—Immune System—HLA-DRB4—multiple sclerosis	0.000636	0.00216	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—TGFB1—multiple sclerosis	0.000636	0.00216	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—MAPK1—multiple sclerosis	0.000623	0.00212	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—IFIH1—multiple sclerosis	0.000609	0.00207	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CIITA—multiple sclerosis	0.000601	0.00204	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—TGFB1—multiple sclerosis	0.000572	0.00194	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—TNFAIP3—multiple sclerosis	0.00057	0.00194	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—MAPK1—multiple sclerosis	0.000561	0.00191	CbGpPWpGaD
Rasagiline—BCL2—Immune System—C4A—multiple sclerosis	0.000559	0.0019	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IL7—multiple sclerosis	0.000559	0.0019	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—MYC—multiple sclerosis	0.000556	0.00189	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—TGFB1—multiple sclerosis	0.000555	0.00189	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—MAPK1—multiple sclerosis	0.000544	0.00185	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PDCD1—multiple sclerosis	0.000535	0.00182	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IL7R—multiple sclerosis	0.000525	0.00179	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CYP27B1—multiple sclerosis	0.000523	0.00178	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CYP24A1—multiple sclerosis	0.000523	0.00178	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CD28—multiple sclerosis	0.000513	0.00174	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—CCR2—multiple sclerosis	0.000504	0.00171	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CBLB—multiple sclerosis	0.000482	0.00164	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—GPC5—multiple sclerosis	0.000478	0.00163	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—IFNB1—multiple sclerosis	0.000465	0.00158	CbGpPWpGaD
Rasagiline—Infestation NOS—Methotrexate—multiple sclerosis	0.000438	0.000621	CcSEcCtD
Rasagiline—Infestation—Methotrexate—multiple sclerosis	0.000438	0.000621	CcSEcCtD
Rasagiline—Rash—Azathioprine—multiple sclerosis	0.000438	0.00062	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000438	0.00062	CcSEcCtD
Rasagiline—Dermatitis—Azathioprine—multiple sclerosis	0.000437	0.00062	CcSEcCtD
Rasagiline—Depression—Methotrexate—multiple sclerosis	0.000437	0.000619	CcSEcCtD
Rasagiline—Ill-defined disorder—Betamethasone—multiple sclerosis	0.000437	0.000619	CcSEcCtD
Rasagiline—Ill-defined disorder—Dexamethasone—multiple sclerosis	0.000437	0.000619	CcSEcCtD
Rasagiline—Discomfort—Triamcinolone—multiple sclerosis	0.000436	0.000618	CcSEcCtD
Rasagiline—Discomfort—Methylprednisolone—multiple sclerosis	0.000435	0.000617	CcSEcCtD
Rasagiline—Headache—Azathioprine—multiple sclerosis	0.000435	0.000616	CcSEcCtD
Rasagiline—Dry mouth—Triamcinolone—multiple sclerosis	0.000432	0.000612	CcSEcCtD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—IL6—multiple sclerosis	0.000431	0.00146	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—MYC—multiple sclerosis	0.000429	0.00146	CbGpPWpGaD
Rasagiline—BCL2—Immune System—MX1—multiple sclerosis	0.000428	0.00146	CbGpPWpGaD
Rasagiline—Stomatitis—Methotrexate—multiple sclerosis	0.000427	0.000606	CcSEcCtD
Rasagiline—Angiopathy—Prednisone—multiple sclerosis	0.000427	0.000605	CcSEcCtD
Rasagiline—Conjunctivitis—Methotrexate—multiple sclerosis	0.000426	0.000604	CcSEcCtD
Rasagiline—Confusional state—Methylprednisolone—multiple sclerosis	0.000426	0.000604	CcSEcCtD
Rasagiline—Immune system disorder—Prednisone—multiple sclerosis	0.000425	0.000603	CcSEcCtD
Rasagiline—Malaise—Dexamethasone—multiple sclerosis	0.000425	0.000601	CcSEcCtD
Rasagiline—Malaise—Betamethasone—multiple sclerosis	0.000425	0.000601	CcSEcCtD
Rasagiline—Vertigo—Dexamethasone—multiple sclerosis	0.000423	0.000599	CcSEcCtD
Rasagiline—Vertigo—Betamethasone—multiple sclerosis	0.000423	0.000599	CcSEcCtD
Rasagiline—Syncope—Dexamethasone—multiple sclerosis	0.000422	0.000598	CcSEcCtD
Rasagiline—Syncope—Betamethasone—multiple sclerosis	0.000422	0.000598	CcSEcCtD
Rasagiline—Infection—Triamcinolone—multiple sclerosis	0.000421	0.000596	CcSEcCtD
Rasagiline—Sweating—Methotrexate—multiple sclerosis	0.00042	0.000596	CcSEcCtD
Rasagiline—Infection—Methylprednisolone—multiple sclerosis	0.00042	0.000595	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—MAPK1—multiple sclerosis	0.000419	0.00143	CbGpPWpGaD
Rasagiline—Haematuria—Methotrexate—multiple sclerosis	0.000418	0.000592	CcSEcCtD
Rasagiline—Shock—Triamcinolone—multiple sclerosis	0.000417	0.00059	CcSEcCtD
Rasagiline—Insomnia—Prednisolone—multiple sclerosis	0.000416	0.00059	CcSEcCtD
Rasagiline—Alopecia—Prednisone—multiple sclerosis	0.000416	0.00059	CcSEcCtD
Rasagiline—Shock—Methylprednisolone—multiple sclerosis	0.000416	0.000589	CcSEcCtD
Rasagiline—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000414	0.000587	CcSEcCtD
Rasagiline—BCL2—Immune System—HLA-DRA—multiple sclerosis	0.000414	0.00141	CbGpPWpGaD
Rasagiline—Loss of consciousness—Betamethasone—multiple sclerosis	0.000414	0.000586	CcSEcCtD
Rasagiline—Loss of consciousness—Dexamethasone—multiple sclerosis	0.000414	0.000586	CcSEcCtD
Rasagiline—Epistaxis—Methotrexate—multiple sclerosis	0.000414	0.000586	CcSEcCtD
Rasagiline—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000414	0.000586	CcSEcCtD
Rasagiline—Paraesthesia—Prednisolone—multiple sclerosis	0.000413	0.000586	CcSEcCtD
Rasagiline—Mental disorder—Prednisone—multiple sclerosis	0.000413	0.000585	CcSEcCtD
Rasagiline—Nausea—Azathioprine—multiple sclerosis	0.000412	0.000584	CcSEcCtD
Rasagiline—Skin disorder—Methylprednisolone—multiple sclerosis	0.00041	0.000581	CcSEcCtD
Rasagiline—Malnutrition—Prednisone—multiple sclerosis	0.00041	0.000581	CcSEcCtD
Rasagiline—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000409	0.00058	CcSEcCtD
Rasagiline—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000408	0.000579	CcSEcCtD
Rasagiline—Convulsion—Dexamethasone—multiple sclerosis	0.000408	0.000578	CcSEcCtD
Rasagiline—Convulsion—Betamethasone—multiple sclerosis	0.000408	0.000578	CcSEcCtD
Rasagiline—Hypertension—Betamethasone—multiple sclerosis	0.000406	0.000576	CcSEcCtD
Rasagiline—Hypertension—Dexamethasone—multiple sclerosis	0.000406	0.000576	CcSEcCtD
Rasagiline—Asthenia—Mitoxantrone—multiple sclerosis	0.000403	0.000571	CcSEcCtD
Rasagiline—Anxiety—Dexamethasone—multiple sclerosis	0.000399	0.000566	CcSEcCtD
Rasagiline—Anxiety—Betamethasone—multiple sclerosis	0.000399	0.000566	CcSEcCtD
Rasagiline—MAOB—Metabolism—RRM1—multiple sclerosis	0.000396	0.00135	CbGpPWpGaD
Rasagiline—Discomfort—Dexamethasone—multiple sclerosis	0.000396	0.000561	CcSEcCtD
Rasagiline—Discomfort—Betamethasone—multiple sclerosis	0.000396	0.000561	CcSEcCtD
Rasagiline—Haemoglobin—Methotrexate—multiple sclerosis	0.000396	0.00056	CcSEcCtD
Rasagiline—Hypotension—Methylprednisolone—multiple sclerosis	0.000395	0.000559	CcSEcCtD
Rasagiline—Haemorrhage—Methotrexate—multiple sclerosis	0.000394	0.000558	CcSEcCtD
Rasagiline—BCL2—Apoptosis—TNF—multiple sclerosis	0.000391	0.00133	CbGpPWpGaD
Rasagiline—BCL2—Immune System—NOD1—multiple sclerosis	0.000391	0.00133	CbGpPWpGaD
Rasagiline—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000389	0.000551	CcSEcCtD
Rasagiline—Urethral disorder—Methotrexate—multiple sclerosis	0.000386	0.000547	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000386	0.000547	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000385	0.000545	CcSEcCtD
Rasagiline—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000384	0.000544	CcSEcCtD
Rasagiline—Insomnia—Triamcinolone—multiple sclerosis	0.000383	0.000543	CcSEcCtD
Rasagiline—Insomnia—Methylprednisolone—multiple sclerosis	0.000382	0.000541	CcSEcCtD
Rasagiline—Infection—Dexamethasone—multiple sclerosis	0.000382	0.000541	CcSEcCtD
Rasagiline—Infection—Betamethasone—multiple sclerosis	0.000382	0.000541	CcSEcCtD
Rasagiline—Ill-defined disorder—Prednisone—multiple sclerosis	0.00038	0.000539	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	0.00038	0.00129	CbGpPWpGaD
Rasagiline—Paraesthesia—Triamcinolone—multiple sclerosis	0.00038	0.000539	CcSEcCtD
Rasagiline—Feeling abnormal—Prednisolone—multiple sclerosis	0.000379	0.000538	CcSEcCtD
Rasagiline—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000379	0.000538	CcSEcCtD
Rasagiline—Anaemia—Prednisone—multiple sclerosis	0.000379	0.000537	CcSEcCtD
Rasagiline—Shock—Dexamethasone—multiple sclerosis	0.000378	0.000536	CcSEcCtD
Rasagiline—Shock—Betamethasone—multiple sclerosis	0.000378	0.000536	CcSEcCtD
Rasagiline—Dyspnoea—Triamcinolone—multiple sclerosis	0.000378	0.000535	CcSEcCtD
Rasagiline—BCL2—Immune System—MALT1—multiple sclerosis	0.000377	0.00128	CbGpPWpGaD
Rasagiline—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000377	0.000534	CcSEcCtD
Rasagiline—Nervous system disorder—Betamethasone—multiple sclerosis	0.000377	0.000534	CcSEcCtD
Rasagiline—Agitation—Prednisone—multiple sclerosis	0.000377	0.000534	CcSEcCtD
Rasagiline—Dyspepsia—Triamcinolone—multiple sclerosis	0.000373	0.000528	CcSEcCtD
Rasagiline—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000372	0.000527	CcSEcCtD
Rasagiline—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000371	0.000526	CcSEcCtD
Rasagiline—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000371	0.000526	CcSEcCtD
Rasagiline—BCL2—Immune System—IRF5—multiple sclerosis	0.000371	0.00126	CbGpPWpGaD
Rasagiline—Malaise—Prednisone—multiple sclerosis	0.00037	0.000524	CcSEcCtD
Rasagiline—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.00037	0.00126	CbGpPWpGaD
Rasagiline—Vertigo—Prednisone—multiple sclerosis	0.000368	0.000522	CcSEcCtD
Rasagiline—Eye disorder—Methotrexate—multiple sclerosis	0.000368	0.000521	CcSEcCtD
Rasagiline—Syncope—Prednisone—multiple sclerosis	0.000368	0.000521	CcSEcCtD
Rasagiline—Anorexia—Betamethasone—multiple sclerosis	0.000366	0.000519	CcSEcCtD
Rasagiline—Anorexia—Dexamethasone—multiple sclerosis	0.000366	0.000519	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—CD86—multiple sclerosis	0.000366	0.00124	CbGpPWpGaD
Rasagiline—Urticaria—Prednisolone—multiple sclerosis	0.000366	0.000518	CcSEcCtD
Rasagiline—Cardiac disorder—Methotrexate—multiple sclerosis	0.000365	0.000518	CcSEcCtD
Rasagiline—Loss of consciousness—Prednisone—multiple sclerosis	0.00036	0.000511	CcSEcCtD
Rasagiline—Hypotension—Dexamethasone—multiple sclerosis	0.000359	0.000509	CcSEcCtD
Rasagiline—Hypotension—Betamethasone—multiple sclerosis	0.000359	0.000509	CcSEcCtD
Rasagiline—Angiopathy—Methotrexate—multiple sclerosis	0.000357	0.000506	CcSEcCtD
Rasagiline—Vomiting—Mitoxantrone—multiple sclerosis	0.000357	0.000506	CcSEcCtD
Rasagiline—Immune system disorder—Methotrexate—multiple sclerosis	0.000356	0.000504	CcSEcCtD
Rasagiline—Convulsion—Prednisone—multiple sclerosis	0.000355	0.000503	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	0.000355	0.00121	CbGpPWpGaD
Rasagiline—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000355	0.000503	CcSEcCtD
Rasagiline—BCL2—Immune System—HLA-G—multiple sclerosis	0.000355	0.00121	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IRF8—multiple sclerosis	0.000355	0.00121	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IFIH1—multiple sclerosis	0.000355	0.00121	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	0.000354	0.0012	CbGpPWpGaD
Rasagiline—Hypertension—Prednisone—multiple sclerosis	0.000354	0.000501	CcSEcCtD
Rasagiline—Rash—Mitoxantrone—multiple sclerosis	0.000354	0.000501	CcSEcCtD
Rasagiline—Dermatitis—Mitoxantrone—multiple sclerosis	0.000354	0.000501	CcSEcCtD
Rasagiline—Chills—Methotrexate—multiple sclerosis	0.000353	0.0005	CcSEcCtD
Rasagiline—Headache—Mitoxantrone—multiple sclerosis	0.000352	0.000498	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.00035	0.000496	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.00035	0.000496	CcSEcCtD
Rasagiline—Arthralgia—Prednisone—multiple sclerosis	0.000349	0.000495	CcSEcCtD
Rasagiline—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000349	0.000494	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—MAPK1—multiple sclerosis	0.000349	0.00119	CbGpPWpGaD
Rasagiline—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000348	0.000493	CcSEcCtD
Rasagiline—Anxiety—Prednisone—multiple sclerosis	0.000348	0.000493	CcSEcCtD
Rasagiline—Alopecia—Methotrexate—multiple sclerosis	0.000348	0.000493	CcSEcCtD
Rasagiline—Insomnia—Betamethasone—multiple sclerosis	0.000348	0.000492	CcSEcCtD
Rasagiline—Insomnia—Dexamethasone—multiple sclerosis	0.000348	0.000492	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	0.000347	0.00118	CbGpPWpGaD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000347	0.000491	CcSEcCtD
Rasagiline—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000345	0.000489	CcSEcCtD
Rasagiline—Paraesthesia—Betamethasone—multiple sclerosis	0.000345	0.000489	CcSEcCtD
Rasagiline—Paraesthesia—Dexamethasone—multiple sclerosis	0.000345	0.000489	CcSEcCtD
Rasagiline—Discomfort—Prednisone—multiple sclerosis	0.000345	0.000489	CcSEcCtD
Rasagiline—Mental disorder—Methotrexate—multiple sclerosis	0.000345	0.000489	CcSEcCtD
Rasagiline—Malnutrition—Methotrexate—multiple sclerosis	0.000343	0.000485	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—HLA-B—multiple sclerosis	0.000341	0.00116	CbGpPWpGaD
Rasagiline—Hypersensitivity—Prednisolone—multiple sclerosis	0.000339	0.000481	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	0.000339	0.00115	CbGpPWpGaD
Rasagiline—Dyspepsia—Dexamethasone—multiple sclerosis	0.000338	0.000479	CcSEcCtD
Rasagiline—Dyspepsia—Betamethasone—multiple sclerosis	0.000338	0.000479	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	0.000338	0.00115	CbGpPWpGaD
Rasagiline—Urticaria—Triamcinolone—multiple sclerosis	0.000336	0.000477	CcSEcCtD
Rasagiline—Urticaria—Methylprednisolone—multiple sclerosis	0.000336	0.000476	CcSEcCtD
Rasagiline—Dysgeusia—Methotrexate—multiple sclerosis	0.000336	0.000475	CcSEcCtD
Rasagiline—Body temperature increased—Triamcinolone—multiple sclerosis	0.000335	0.000474	CcSEcCtD
Rasagiline—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000334	0.000473	CcSEcCtD
Rasagiline—Decreased appetite—Betamethasone—multiple sclerosis	0.000334	0.000473	CcSEcCtD
Rasagiline—Decreased appetite—Dexamethasone—multiple sclerosis	0.000334	0.000473	CcSEcCtD
Rasagiline—Nausea—Mitoxantrone—multiple sclerosis	0.000333	0.000472	CcSEcCtD
Rasagiline—Infection—Prednisone—multiple sclerosis	0.000332	0.000471	CcSEcCtD
Rasagiline—BCL2—Immune System—TNFAIP3—multiple sclerosis	0.000332	0.00113	CbGpPWpGaD
Rasagiline—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000332	0.00047	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000332	0.00047	CcSEcCtD
Rasagiline—Back pain—Methotrexate—multiple sclerosis	0.000331	0.00047	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	0.000331	0.00112	CbGpPWpGaD
Rasagiline—Shock—Prednisone—multiple sclerosis	0.000329	0.000466	CcSEcCtD
Rasagiline—Nervous system disorder—Prednisone—multiple sclerosis	0.000328	0.000465	CcSEcCtD
Rasagiline—Skin disorder—Prednisone—multiple sclerosis	0.000325	0.00046	CcSEcCtD
Rasagiline—Hyperhidrosis—Prednisone—multiple sclerosis	0.000323	0.000458	CcSEcCtD
Rasagiline—Anorexia—Prednisone—multiple sclerosis	0.000319	0.000452	CcSEcCtD
Rasagiline—Ill-defined disorder—Methotrexate—multiple sclerosis	0.000318	0.00045	CcSEcCtD
Rasagiline—Anaemia—Methotrexate—multiple sclerosis	0.000317	0.000449	CcSEcCtD
Rasagiline—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000317	0.000449	CcSEcCtD
Rasagiline—Feeling abnormal—Betamethasone—multiple sclerosis	0.000317	0.000449	CcSEcCtD
Rasagiline—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000314	0.000445	CcSEcCtD
Rasagiline—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000314	0.000445	CcSEcCtD
Rasagiline—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000312	0.000442	CcSEcCtD
Rasagiline—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000311	0.000441	CcSEcCtD
Rasagiline—Malaise—Methotrexate—multiple sclerosis	0.000309	0.000438	CcSEcCtD
Rasagiline—Vertigo—Methotrexate—multiple sclerosis	0.000308	0.000436	CcSEcCtD
Rasagiline—Leukopenia—Methotrexate—multiple sclerosis	0.000307	0.000435	CcSEcCtD
Rasagiline—Urticaria—Dexamethasone—multiple sclerosis	0.000305	0.000432	CcSEcCtD
Rasagiline—Urticaria—Betamethasone—multiple sclerosis	0.000305	0.000432	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000305	0.000432	CcSEcCtD
Rasagiline—Dizziness—Prednisolone—multiple sclerosis	0.000304	0.000431	CcSEcCtD
Rasagiline—Asthenia—Triamcinolone—multiple sclerosis	0.000304	0.00043	CcSEcCtD
Rasagiline—Abdominal pain—Betamethasone—multiple sclerosis	0.000304	0.00043	CcSEcCtD
Rasagiline—Abdominal pain—Dexamethasone—multiple sclerosis	0.000304	0.00043	CcSEcCtD
Rasagiline—Body temperature increased—Betamethasone—multiple sclerosis	0.000304	0.00043	CcSEcCtD
Rasagiline—Body temperature increased—Dexamethasone—multiple sclerosis	0.000304	0.00043	CcSEcCtD
Rasagiline—Asthenia—Methylprednisolone—multiple sclerosis	0.000303	0.000429	CcSEcCtD
Rasagiline—Insomnia—Prednisone—multiple sclerosis	0.000303	0.000429	CcSEcCtD
Rasagiline—Paraesthesia—Prednisone—multiple sclerosis	0.0003	0.000426	CcSEcCtD
Rasagiline—CYP1A2—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.0003	0.00102	CbGpPWpGaD
Rasagiline—Pruritus—Triamcinolone—multiple sclerosis	0.0003	0.000424	CcSEcCtD
Rasagiline—Cough—Methotrexate—multiple sclerosis	0.000299	0.000424	CcSEcCtD
Rasagiline—Pruritus—Methylprednisolone—multiple sclerosis	0.000299	0.000424	CcSEcCtD
Rasagiline—BCL2—Immune System—CD28—multiple sclerosis	0.000299	0.00102	CbGpPWpGaD
Rasagiline—Convulsion—Methotrexate—multiple sclerosis	0.000297	0.000421	CcSEcCtD
Rasagiline—Dyspepsia—Prednisone—multiple sclerosis	0.000295	0.000417	CcSEcCtD
Rasagiline—BCL2—Immune System—PTPRC—multiple sclerosis	0.000293	0.000997	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CCR2—multiple sclerosis	0.000293	0.000997	CbGpPWpGaD
Rasagiline—Arthralgia—Methotrexate—multiple sclerosis	0.000292	0.000413	CcSEcCtD
Rasagiline—Chest pain—Methotrexate—multiple sclerosis	0.000292	0.000413	CcSEcCtD
Rasagiline—Decreased appetite—Prednisone—multiple sclerosis	0.000291	0.000412	CcSEcCtD
Rasagiline—Rash—Prednisolone—multiple sclerosis	0.00029	0.000411	CcSEcCtD
Rasagiline—Dermatitis—Prednisolone—multiple sclerosis	0.00029	0.000411	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.00029	0.00041	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—TLR4—multiple sclerosis	0.000289	0.000984	CbGpPWpGaD
Rasagiline—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000289	0.00041	CcSEcCtD
Rasagiline—Headache—Prednisolone—multiple sclerosis	0.000288	0.000409	CcSEcCtD
Rasagiline—Discomfort—Methotrexate—multiple sclerosis	0.000288	0.000408	CcSEcCtD
Rasagiline—Constipation—Prednisone—multiple sclerosis	0.000286	0.000405	CcSEcCtD
Rasagiline—BCL2—Immune System—HLA-DPB1—multiple sclerosis	0.000284	0.000964	CbGpPWpGaD
Rasagiline—Confusional state—Methotrexate—multiple sclerosis	0.000282	0.000399	CcSEcCtD
Rasagiline—Dizziness—Triamcinolone—multiple sclerosis	0.00028	0.000397	CcSEcCtD
Rasagiline—Dizziness—Methylprednisolone—multiple sclerosis	0.000279	0.000396	CcSEcCtD
Rasagiline—Infection—Methotrexate—multiple sclerosis	0.000278	0.000394	CcSEcCtD
Rasagiline—Feeling abnormal—Prednisone—multiple sclerosis	0.000276	0.000391	CcSEcCtD
Rasagiline—Asthenia—Betamethasone—multiple sclerosis	0.000276	0.000391	CcSEcCtD
Rasagiline—Asthenia—Dexamethasone—multiple sclerosis	0.000276	0.000391	CcSEcCtD
Rasagiline—Nervous system disorder—Methotrexate—multiple sclerosis	0.000274	0.000389	CcSEcCtD
Rasagiline—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000274	0.000388	CcSEcCtD
Rasagiline—Nausea—Prednisolone—multiple sclerosis	0.000274	0.000388	CcSEcCtD
Rasagiline—BCL2—Immune System—CD40—multiple sclerosis	0.000273	0.000927	CbGpPWpGaD
Rasagiline—BCL2—Immune System—ITGA4—multiple sclerosis	0.000273	0.000927	CbGpPWpGaD
Rasagiline—Pruritus—Dexamethasone—multiple sclerosis	0.000272	0.000385	CcSEcCtD
Rasagiline—Pruritus—Betamethasone—multiple sclerosis	0.000272	0.000385	CcSEcCtD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000272	0.000924	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000272	0.000924	CbGpPWpGaD
Rasagiline—Skin disorder—Methotrexate—multiple sclerosis	0.000272	0.000385	CcSEcCtD
Rasagiline—BCL2—Immune System—IFNB1—multiple sclerosis	0.000271	0.00092	CbGpPWpGaD
Rasagiline—Hyperhidrosis—Methotrexate—multiple sclerosis	0.00027	0.000383	CcSEcCtD
Rasagiline—Vomiting—Triamcinolone—multiple sclerosis	0.000269	0.000381	CcSEcCtD
Rasagiline—BCL2—Immune System—CTLA4—multiple sclerosis	0.000269	0.000914	CbGpPWpGaD
Rasagiline—Vomiting—Methylprednisolone—multiple sclerosis	0.000269	0.000381	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—CD80—multiple sclerosis	0.000267	0.000908	CbGpPWpGaD
Rasagiline—Rash—Triamcinolone—multiple sclerosis	0.000267	0.000378	CcSEcCtD
Rasagiline—Dermatitis—Triamcinolone—multiple sclerosis	0.000267	0.000378	CcSEcCtD
Rasagiline—Anorexia—Methotrexate—multiple sclerosis	0.000267	0.000378	CcSEcCtD
Rasagiline—Rash—Methylprednisolone—multiple sclerosis	0.000266	0.000377	CcSEcCtD
Rasagiline—Dermatitis—Methylprednisolone—multiple sclerosis	0.000266	0.000377	CcSEcCtD
Rasagiline—Urticaria—Prednisone—multiple sclerosis	0.000266	0.000377	CcSEcCtD
Rasagiline—Headache—Triamcinolone—multiple sclerosis	0.000265	0.000376	CcSEcCtD
Rasagiline—Headache—Methylprednisolone—multiple sclerosis	0.000265	0.000375	CcSEcCtD
Rasagiline—Abdominal pain—Prednisone—multiple sclerosis	0.000265	0.000375	CcSEcCtD
Rasagiline—Body temperature increased—Prednisone—multiple sclerosis	0.000265	0.000375	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	0.000264	0.000898	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	0.000264	0.000896	CbGpPWpGaD
Rasagiline—Diarrhoea—Dexamethasone—multiple sclerosis	0.000263	0.000372	CcSEcCtD
Rasagiline—Diarrhoea—Betamethasone—multiple sclerosis	0.000263	0.000372	CcSEcCtD
Rasagiline—Hypotension—Methotrexate—multiple sclerosis	0.000261	0.00037	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	0.000259	0.000879	CbGpPWpGaD
Rasagiline—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000255	0.000361	CcSEcCtD
Rasagiline—Dizziness—Betamethasone—multiple sclerosis	0.000254	0.00036	CcSEcCtD
Rasagiline—Dizziness—Dexamethasone—multiple sclerosis	0.000254	0.00036	CcSEcCtD
Rasagiline—Insomnia—Methotrexate—multiple sclerosis	0.000253	0.000358	CcSEcCtD
Rasagiline—Nausea—Triamcinolone—multiple sclerosis	0.000252	0.000356	CcSEcCtD
Rasagiline—Paraesthesia—Methotrexate—multiple sclerosis	0.000251	0.000356	CcSEcCtD
Rasagiline—Nausea—Methylprednisolone—multiple sclerosis	0.000251	0.000356	CcSEcCtD
Rasagiline—Dyspnoea—Methotrexate—multiple sclerosis	0.000249	0.000353	CcSEcCtD
Rasagiline—Somnolence—Methotrexate—multiple sclerosis	0.000249	0.000352	CcSEcCtD
Rasagiline—Hypersensitivity—Prednisone—multiple sclerosis	0.000247	0.000349	CcSEcCtD
Rasagiline—Dyspepsia—Methotrexate—multiple sclerosis	0.000246	0.000349	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	0.000246	0.000837	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	0.000246	0.000837	CbGpPWpGaD
Rasagiline—Vomiting—Betamethasone—multiple sclerosis	0.000244	0.000346	CcSEcCtD
Rasagiline—Vomiting—Dexamethasone—multiple sclerosis	0.000244	0.000346	CcSEcCtD
Rasagiline—Decreased appetite—Methotrexate—multiple sclerosis	0.000243	0.000344	CcSEcCtD
Rasagiline—Rash—Dexamethasone—multiple sclerosis	0.000242	0.000343	CcSEcCtD
Rasagiline—Rash—Betamethasone—multiple sclerosis	0.000242	0.000343	CcSEcCtD
Rasagiline—Dermatitis—Dexamethasone—multiple sclerosis	0.000242	0.000343	CcSEcCtD
Rasagiline—Dermatitis—Betamethasone—multiple sclerosis	0.000242	0.000343	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000241	0.000342	CcSEcCtD
Rasagiline—Headache—Betamethasone—multiple sclerosis	0.000241	0.000341	CcSEcCtD
Rasagiline—Headache—Dexamethasone—multiple sclerosis	0.000241	0.000341	CcSEcCtD
Rasagiline—Asthenia—Prednisone—multiple sclerosis	0.00024	0.00034	CcSEcCtD
Rasagiline—BCL2—Immune System—VCAM1—multiple sclerosis	0.000237	0.000807	CbGpPWpGaD
Rasagiline—Pruritus—Prednisone—multiple sclerosis	0.000237	0.000335	CcSEcCtD
Rasagiline—BCL2—Immune System—HLA-DQA1—multiple sclerosis	0.000237	0.000805	CbGpPWpGaD
Rasagiline—Feeling abnormal—Methotrexate—multiple sclerosis	0.00023	0.000326	CcSEcCtD
Rasagiline—Diarrhoea—Prednisone—multiple sclerosis	0.000229	0.000324	CcSEcCtD
Rasagiline—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000229	0.000324	CcSEcCtD
Rasagiline—Nausea—Betamethasone—multiple sclerosis	0.000228	0.000323	CcSEcCtD
Rasagiline—Nausea—Dexamethasone—multiple sclerosis	0.000228	0.000323	CcSEcCtD
Rasagiline—MAOB—Metabolism—BCHE—multiple sclerosis	0.000228	0.000774	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—TYK2—multiple sclerosis	0.000225	0.000766	CbGpPWpGaD
Rasagiline—Urticaria—Methotrexate—multiple sclerosis	0.000222	0.000315	CcSEcCtD
Rasagiline—BCL2—Immune System—HLA-DQB1—multiple sclerosis	0.000221	0.000753	CbGpPWpGaD
Rasagiline—Dizziness—Prednisone—multiple sclerosis	0.000221	0.000313	CcSEcCtD
Rasagiline—Abdominal pain—Methotrexate—multiple sclerosis	0.000221	0.000313	CcSEcCtD
Rasagiline—Body temperature increased—Methotrexate—multiple sclerosis	0.000221	0.000313	CcSEcCtD
Rasagiline—BCL2—Immune System—CD86—multiple sclerosis	0.000213	0.000725	CbGpPWpGaD
Rasagiline—Vomiting—Prednisone—multiple sclerosis	0.000213	0.000301	CcSEcCtD
Rasagiline—Rash—Prednisone—multiple sclerosis	0.000211	0.000299	CcSEcCtD
Rasagiline—Dermatitis—Prednisone—multiple sclerosis	0.000211	0.000299	CcSEcCtD
Rasagiline—Headache—Prednisone—multiple sclerosis	0.00021	0.000297	CcSEcCtD
Rasagiline—BCL2—Immune System—CD40LG—multiple sclerosis	0.000209	0.000711	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CD8A—multiple sclerosis	0.000207	0.000703	CbGpPWpGaD
Rasagiline—Hypersensitivity—Methotrexate—multiple sclerosis	0.000206	0.000292	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—CD4—multiple sclerosis	0.000204	0.000693	CbGpPWpGaD
Rasagiline—Asthenia—Methotrexate—multiple sclerosis	0.000201	0.000284	CcSEcCtD
Rasagiline—BCL2—Immune System—HLA-B—multiple sclerosis	0.000199	0.000676	CbGpPWpGaD
Rasagiline—Nausea—Prednisone—multiple sclerosis	0.000199	0.000282	CcSEcCtD
Rasagiline—Pruritus—Methotrexate—multiple sclerosis	0.000198	0.00028	CcSEcCtD
Rasagiline—Diarrhoea—Methotrexate—multiple sclerosis	0.000191	0.000271	CcSEcCtD
Rasagiline—BCL2—Immune System—IL2RA—multiple sclerosis	0.000186	0.000633	CbGpPWpGaD
Rasagiline—Dizziness—Methotrexate—multiple sclerosis	0.000185	0.000262	CcSEcCtD
Rasagiline—BCL2—Immune System—HLA-A—multiple sclerosis	0.000184	0.000626	CbGpPWpGaD
Rasagiline—Vomiting—Methotrexate—multiple sclerosis	0.000178	0.000252	CcSEcCtD
Rasagiline—Rash—Methotrexate—multiple sclerosis	0.000176	0.00025	CcSEcCtD
Rasagiline—Dermatitis—Methotrexate—multiple sclerosis	0.000176	0.00025	CcSEcCtD
Rasagiline—Headache—Methotrexate—multiple sclerosis	0.000175	0.000248	CcSEcCtD
Rasagiline—CYP1A2—Metabolism—SRM—multiple sclerosis	0.000172	0.000584	CbGpPWpGaD
Rasagiline—BCL2—Immune System—TLR4—multiple sclerosis	0.000169	0.000573	CbGpPWpGaD
Rasagiline—BCL2—Immune System—HLA-DRB1—multiple sclerosis	0.000168	0.000572	CbGpPWpGaD
Rasagiline—Nausea—Methotrexate—multiple sclerosis	0.000166	0.000235	CcSEcCtD
Rasagiline—BCL2—Immune System—ICAM1—multiple sclerosis	0.000162	0.000549	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—POMC—multiple sclerosis	0.000159	0.000541	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CD80—multiple sclerosis	0.000156	0.000529	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—MAPK1—multiple sclerosis	0.000143	0.000488	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—APOE—multiple sclerosis	0.000137	0.000465	CbGpPWpGaD
Rasagiline—BCL2—Immune System—TYK2—multiple sclerosis	0.000131	0.000446	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IFNG—multiple sclerosis	0.000123	0.000418	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP24A1—multiple sclerosis	0.000121	0.000411	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP27B1—multiple sclerosis	0.000121	0.000411	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CD4—multiple sclerosis	0.000119	0.000404	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	0.000118	0.000402	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—POMC—multiple sclerosis	0.000118	0.0004	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GPC5—multiple sclerosis	0.000111	0.000376	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—IL6—multiple sclerosis	0.00011	0.000375	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IL1B—multiple sclerosis	0.00011	0.000373	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IL2—multiple sclerosis	0.000109	0.000371	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—ALB—multiple sclerosis	0.000107	0.000364	CbGpPWpGaD
Rasagiline—BCL2—Immune System—STAT3—multiple sclerosis	9.19e-05	0.000312	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—RRM1—multiple sclerosis	9.17e-05	0.000312	CbGpPWpGaD
Rasagiline—BCL2—Immune System—MAPK1—multiple sclerosis	8.36e-05	0.000284	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	7.11e-05	0.000242	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IL6—multiple sclerosis	6.42e-05	0.000218	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	6.11e-05	0.000208	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	5.57e-05	0.000189	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—BCHE—multiple sclerosis	5.27e-05	0.000179	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—APOE—multiple sclerosis	3.17e-05	0.000108	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—POMC—multiple sclerosis	2.72e-05	9.25e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ALB—multiple sclerosis	2.48e-05	8.44e-05	CbGpPWpGaD
